Showing results (331-340 of 592) with videos related to
Sort By:
Pageof 60
Future Oncology (London, England)|December 19, 2019
Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivityAntonio Frassoldati, Laura Biganzoli, Roberto Bordonaro, et al.Journal of Neuro-Oncology|November 18, 2016
Beyond breast specific-Graded Prognostic Assessment in patients with brain metastases from breast cancer: treatment impact on outcomeGaia Griguolo, Maria Vittoria Dieci, Tommaso Giarratano, et al.Cancer Treatment Reviews|April 17, 2022
Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and managementSandra M Swain, Mizuki Nishino, Lisa H Lancaster, et al.Journal for Immunotherapy of Cancer|September 4, 2021
Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancerCarmine Carbone, Geny Piro, Antonio Agostini, et al.Immunotherapy|June 4, 2019
PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysisAntonio Rossi, Vincenzo Di Noia, Anastasios Gkountakos, et al.Therapeutic Advances in Medical Oncology|June 7, 2023
Adjuvant denosumab in early breast cancer: a systematic review and meta-analysis of randomized controlled clinical trialsLuca Mastrantoni, Giovanna Garufi, Elena Di Monte, et al.Clinical Breast Cancer|July 19, 2014
Human epidermal growth factor receptor 2-positive breast cancer: heat shock protein 90 overexpression, Ki67 proliferative index, and topoisomerase II-α co-amplification as predictors of pathologic complete response to neoadjuvant chemotherapy with trastuzumab and docetaxelEmilio Bria, Jenny Furlanetto, Luisa Carbognin, et al.European Journal of Cancer (Oxford, England : 1990)|August 26, 2019
Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trialMark Robson, Kathryn J Ruddy, Seock-Ah Im, et al.Biomedicines|October 27, 2022
Interleukin-8 in Colorectal Cancer: A Systematic Review and Meta-Analysis of Its Potential Role as a Prognostic BiomarkerChiara Bazzichetto, Michele Milella, Ilaria Zampiva, et al.Targeted Oncology|September 1, 2018
Comparison Between Prognostic Classifications in De Novo Metastatic Hormone Sensitive Prostate CancerRoberto Iacovelli, Chiara Ciccarese, Claudia Mosillo, et al.Pageof 60